Corporation
Sandoz Canada Inc.
- Meetings this Parliament
- 16
- With MPs
- 2
- Since Nov 2021
- 51
- Active registrations
- 1
Most recent reported meeting: Oct 29, 2026.
Lobbying by Sandoz Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingBills they've lobbied on
Named in their own descriptions of meetings or of their registration. Their words are quoted below each bill.
-
Bill C-64 44-1 (previous Parliament) 4 mentions · latest Nov 19, 2024 In registration
“Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.”
Who they meet
Since the current Parliament opened.
MPs
- Marjorie Michel Liberal 1
- Mélanie Joly Liberal 1
Institutions
- Innovation, Science and Economic Development Canada (ISED)10
- Health Canada (HC)8
Registrations in effect
In-house (corporation) In effect since Jun 16, 2026
Filed by Michel Robidoux, President & Chief Executive Officer
Lobbyists
- Catherine Rousseau · Senior director, BioGx Market Access
- Christian Ouellet · Vice-président Affaires corporatives
- Guillaume Lefevre · Director, Government Affairs
- Sonia Gallo · Vice-President, Regulatory Affairs
Institutions they may lobby: Canada Border Services Agency (CBSA), Canada Revenue Agency (CRA), Competition Tribunal (CT), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Invest in Canada Hub, Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Transport Canada (TC), Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (14)Hide details
- "In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
- Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.
- Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) and re-negotiation of NAFTA with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.
- Provide input into Government of Canada's Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.
- Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.
- Innovation, Science & Economic Development Canada regarding export provisions of the Patent Act (pharmaceuticals).
- Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.
- Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.
- Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
- Health Canada regarding regulation about Requirement for reporting of drug shortages.
- Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program
- Health Canada, Innovation, Science & Economic Development Canada and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.
- As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.
- As a member company, participation in the Canadian Generic Pharmaceutical Association's legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to the extended period of data exclusivity, as well as further proposed amendments to these regulations.
Registration 768899-234283-37. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Michel Robidoux · In-house (corporation)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
- Justine Frame · Conseillère en politiques, Health Canada (HC)
Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions. Read more
Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
-
Reported by Michel Robidoux · In-house (corporation)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
- Justine Frame · Conseillère en politiques, Health Canada (HC)
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans." Read more
-
Reported by Michel Robidoux · In-house (corporation)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans." Read more
-
Reported by Michel Robidoux · In-house (corporation)
- Justine Frame · Conseillère en politiques, Health Canada (HC)
- Sandenga Yeba · Directeur des politiques et chef de cabinet adjoint, Health Canada (HC)
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans." Read more
-
Reported by Michel Robidoux · In-house (corporation)
- Justine Frame · Conseillère en politiques, Health Canada (HC)
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans." Read more
-
Reported by Michel Robidoux · In-house (corporation)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
- Ian Burke Cameron · Directeur de la planification stratégique et conseiller princ., Innovation, Science and Economic Development Canada (ISED)
Provide input into Government of Canada's Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation. Read more
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.
-
Reported by Michel Robidoux · In-house (corporation)
- Marjorie Michel · Ministre de la santé, Health Canada (HC)
- Sandenga Yeba · Directeur des politiques et chef de cabinet adjoint, Health Canada (HC)
Health Canada regarding regulation about Requirement for reporting of drug shortages. Read more
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
-
Reported by Michel Robidoux · In-house (corporation)
- Mélanie Joly · Ministre de l'Industrie et ministre responsable pour le développement économique Canada pour les régions du Québec, Innovation, Science and Economic Development Canada (ISED)
- Paul Moen · Directeur de cabinet, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans." Read more
-
Reported by Michel Robidoux · In-house (corporation)
- Sandenga Yeba · Directeur de cabinet adjoint, Health Canada (HC)
Health Canada regarding regulation about Requirement for reporting of drug shortages. Read more
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
-
Reported by Michel Robidoux · In-house (corporation)
- Manuela Tomic · Conseillère principale, Innovation, Science and Economic Development Canada (ISED)
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans." Read more
-
Reported by Michel Robidoux · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans." Read more
-
Reported by Michel Robidoux · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans." Read more
-
Reported by Michel Robidoux · In-house (corporation)
- Sandenga Yeba · Directeur de cabinet adjoint, Health Canada (HC)
Health Canada regarding regulation about Requirement for reporting of drug shortages. Read more
Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.
Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program
Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
-
Reported by Michel Robidoux · In-house (corporation)
- Paul Moen · Directeur de cabinet, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Conseillère principale, Innovation, Science and Economic Development Canada (ISED)
- Cédrick Devedeux Delorme · Conseiller politique, Innovation, Science and Economic Development Canada (ISED)
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector. Read more
Health Canada regarding regulation about Requirement for reporting of drug shortages.
Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.
-
Reported by Michel Robidoux · In-house (corporation)
- Paul Moen · Directeur de cabinet, Innovation, Science and Economic Development Canada (ISED)
Provide input into Government of Canada's Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation. Read more
Health Canada regarding regulation about Requirement for reporting of drug shortages.
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.
Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.
Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.
-
Reported by Michel Robidoux · In-house (corporation)
- Sandenga Yeba · Directeur de cabinet adjoint, Health Canada (HC)
Health Canada regarding regulation about Requirement for reporting of drug shortages. Read more
Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.
Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program
-
Reported by Michel Robidoux · In-house (corporation)
- Xavier Barsalou-Duval · Député
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector. Read more
Health Canada regarding regulation about Requirement for reporting of drug shortages.
-
Reported by Michel Robidoux · In-house (corporation)
- Eshan Naik · Directeur des politiques, Health Canada (HC)
Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply. Read more
Health Canada regarding the Cannabis Act (C-45) for medicinal cannabis
-
Reported by Michel Robidoux · In-house (corporation)
- Laurel Chester · Conseiller(ère) princ., Innovation, Science and Economic Development Canada (ISED)
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector. Read more
-
Reported by Michel Robidoux · In-house (corporation)
- Luc Thériault · Député
Health Canada regarding the Cannabis Act (C-45) for medicinal cannabis
-
Reported by Michel Robidoux · In-house (corporation)
- Eshan Naik · Directeur des politiques, Health Canada (HC)
Health Canada regarding regulation about Requirement for reporting of drug shortages. Read more
Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.
Health Canada regarding the Cannabis Act (C-45) for medicinal cannabis
-
Reported by Michel Robidoux · In-house (corporation)
- Clément Gignac · Sénateur, Senate of Canada
- Rod Legget · Conseillet politique, Senate of Canada
Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.
-
Reported by Michel Robidoux · In-house (corporation)
- Eshan Naik · Directeur des politiques, Health Canada (HC)
Economic DevelopmentHealth
-
Reported by Michel Robidoux · In-house (corporation)
- Dylan Bissonnette · Conseiller principal, Health Canada (HC)
Health
-
Reported by Michel Robidoux · In-house (corporation)
- Laurel Chester · Conseillère Principale, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthIndustry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.